Ultram®
Tramadol · oral tablet
Analgesics
Approved uses
Pain in adults severe enough to require an opioid analgesic and for which alternative treatments are inadequate (non-ocular; the only approved indication)
Titrate from 25 mg QD by 25 mg every 3 days to 100 mg per day (25 mg QID), then by 50 mg as tolerated every 3 days to 200 mg per day (50 mg QID), then 50 to 100 mg every 4 to 6 hours as needed, maximum 400 mg per day; when rapid onset is required and the benefits outweigh the risk of discontinuation due to adverse events at higher initial doses, 50 to 100 mg every 4 to 6 hours as needed from the start
Contraindications
- Children younger than 12 years
- Postoperative management in children younger than 18 years following tonsillectomy or adenoidectomy
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to tramadol, any other component of the product, or opioids
- Concurrent monoamine oxidase inhibitor use, or MAOI use within the last 14 days
Tablets: tramadol hydrochloride 50 mg (equivalent to 43.9 mg base), scored; bottle of 100 tablets
Opioid agonist that also weakly inhibits norepinephrine and serotonin reuptake; opioid activity comes from low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to mu-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in mu-opioid binding. Analgesia begins about one hour after a dose and peaks at two to three hours.
Warnings & Precautions
- Boxed warning, addiction and abuse: Schedule IV opioid that exposes users to the risks of addiction, abuse, and misuse, which can lead to overdose and death; addiction can occur at recommended dosages.
- Boxed warning, respiratory depression: Serious, life-threatening, or fatal respiratory depression can occur, with the greatest risk during initiation and after a dose increase; monitor closely, especially within the first 24 to 72 hours of therapy and after each increase. Discuss the availability of naloxone when initiating and renewing treatment.
- Boxed warning, accidental ingestion: A single dose can be fatal, especially in a child.
- Boxed warning, pediatric ultra-rapid metabolism: Life-threatening respiratory depression and death have occurred in children who received tramadol; CYP2D6 ultra-rapid metabolizers form higher than expected M1 levels and should not use ULTRAM. Contraindicated under 12 years and after tonsillectomy or adenoidectomy under 18 years; avoid in adolescents 12 to 18 with hypoventilation risk factors such as obstructive sleep apnea, obesity, or severe pulmonary disease unless the benefits outweigh the risks.
- Boxed warning, neonatal withdrawal: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated; ensure appropriate treatment will be available.
- Boxed warning, cytochrome P450 interactions: Starting or stopping a CYP3A4 inducer, a 3A4 inhibitor, or a 2D6 inhibitor changes tramadol and M1 levels in complex ways. This may increase the risk for serious adverse events including seizures and serotonin syndrome, in some patients may result in signs and symptoms of opioid withdrawal, and may cause potentially fatal respiratory depression; follow patients for these risks.
- Boxed warning, concomitant use with CNS depressants: Concomitant use with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
- Boxed warning, opioid REMS: FDA requires a Risk Evaluation and Mitigation Strategy for opioid analgesics; healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients with every prescription.
- Sleep-related breathing disorders: Opioids can cause central sleep apnea (CSA) and sleep-related hypoxemia, and the risk of CSA rises with dose; consider decreasing the dosage in patients who present with CSA.
- Serotonin syndrome: Potentially life-threatening; cases have been reported with tramadol, particularly during concomitant use with serotonergic drugs such as SSRIs, SNRIs, TCAs, triptans, cyclobenzaprine, linezolid, or intravenous methylene blue, and this may occur within the recommended dosage range. Discontinue ULTRAM if serotonin syndrome is suspected.
- Seizures: Reported within the recommended dosage range, and postmarketing reports indicate that seizure risk is increased above it. SSRIs, TCAs, other opioids, MAOIs, and neuroleptics increase the risk, and risk may also increase with epilepsy, a history of seizures, head trauma, or alcohol and drug withdrawal; in overdose, naloxone may increase the risk of seizure.
- Suicide risk: Not to be prescribed for suicidal or addiction-prone patients; consider a non-narcotic analgesic in suicidal or depressed patients.
- Anaphylaxis: Serious and rarely fatal anaphylactic reactions have been reported, often after the first dose; other reported allergic reactions include angioedema, toxic epidermal necrolysis, and Stevens-Johnson syndrome; discontinue permanently and do not rechallenge with any formulation.
- Acute angle closure: Mydriasis appears among the postmarketing eye disorders on this label. Two single case reports describe bilateral acute angle closure after tramadol. In the subcutaneous case, the patient was a 42-year-old healthy man with unremarkable past medical and ocular history. In the oral case, the authors judged that significant hyperopia and very short axial lengths likely played a dominant role and that oral tramadol may have acted as a permissive factor rather than as a sole causative agent.
- Adrenal insufficiency: Reported with opioid use, more often after more than one month; confirm by testing, give physiologic corticosteroid replacement, and wean off the opioid.
- Respiratory depression in chronic pulmonary disease: Patients with significant chronic obstructive pulmonary disease or cor pulmonale, a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages. Life-threatening respiratory depression is more likely in elderly, cachectic, or debilitated patients; monitor closely, or consider non-opioid analgesics.
- Severe hypotension: ULTRAM may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients, with increased risk after a reduced blood volume or with certain CNS depressant drugs; monitor for hypotension after initiating or titrating the dosage, and avoid use in circulatory shock.
- Increased intracranial pressure: In patients with increased intracranial pressure or brain tumors, ULTRAM may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure; monitor for sedation and respiratory depression. Opioids may also obscure the clinical course after head injury, and use is to be avoided in impaired consciousness or coma.
- Gastrointestinal conditions: Contraindicated in known or suspected gastrointestinal obstruction; tramadol may cause spasm of the sphincter of Oddi and opioids may raise serum amylase, so monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
- Hyponatremia: Sodium below 135 mmol/L reported and often severe, most often in women over 65 and within the first week of therapy; in some reports it resulted from SIADH. Monitor during treatment, and if signs and symptoms are present, initiate appropriate treatment and discontinue ULTRAM.
- Hypoglycemia: Reported cases, some requiring hospitalization, mostly in patients with predisposing risk factors such as diabetes; if suspected, monitor blood glucose and consider discontinuation as appropriate.
- Withdrawal: Do not abruptly discontinue in a patient physically dependent on opioids; gradually taper the dosage, because rapid discontinuation has produced withdrawal, uncontrolled pain, and suicide. Avoid mixed agonist/antagonist or partial agonist analgesics, which may reduce the analgesic effect or precipitate withdrawal.
- Driving and operating machinery: ULTRAM may impair the abilities needed for driving or operating machinery; warn patients not to drive or operate dangerous machinery unless they are tolerant to its effects and know how they will react.
Common Side Effects
Ocular: Miosis and visual disturbance each at 1% to under 5%; mydriasis reported postmarketing; cataracts reported with causal relationship undetermined. Common systemic: Cumulative incidence in chronic nonmalignant pain trials (N=427) at 7 days and at 90 days, dizziness or vertigo 26% and 33%, nausea 24% and 40%, constipation 24% and 46%, headache 18% and 32%, somnolence 16% and 25%, vomiting 9% and 17%, pruritus 8% and 11%. Serious systemic: Respiratory depression, seizures, serotonin syndrome, anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis, QT prolongation and torsade de pointes, hyponatremia and/or SIADH, hypoglycemia, adrenal insufficiency, androgen deficiency with chronic opioid use.
Pregnancy: Data in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage; prolonged use may cause neonatal opioid withdrawal syndrome, and neonatal seizures, fetal death, and stillbirth have been reported postmarketing. Not recommended during or immediately before labor.
Lactation: Breastfeeding not recommended. Drug and the more potent M1 metabolite are present in milk, and an ultra-rapid metabolizer mother may have higher M1 levels in milk that can be dangerous to the infant. Monitor exposed infants for excess sedation and respiratory depression.
Safety and effectiveness not established; contraindicated under 12 years and for post-tonsillectomy or adenoidectomy pain under 18 years; avoid in adolescents 12 to 18 years with other risk factors for respiratory depression unless the benefits outweigh the risks.